Related Experiment Video
Updated: Oct 1, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
A novel nano delivery system targeting different stages of osteoclasts
Bongsong Zhang1, Juzhi Zhao1, Hongji Yan2,3,4
1School of Life Science and Technology, Harbin Institute of Technology, 150080 Harbin, China. tianweiming@hit.edu.cn.
Abstract:
Osteoclast (OC) abnormalities represent osteoporosis's critical mechanism (OP). OCs undergo multiple processes that range from monocytic to functional. Different drugs target OCs at different developmental stages; however, almost no Suitable drug-targeted delivery systems exist. Therefore, we designed two dual-targeting nanoparticles to target OCs at different functional stages. Using the calcitonin gene-related peptide receptor (CGRPR), which OC precursors highly express, and specific TRAPpeptides screened in the bone resorption lacuna, where mature OCs function, respectively, two types of dual-targeted nanoparticles were constructed. Afterwards, nanoparticles were grafted with hyaluronic acid (HA), which specifically binds to CD44 on the surface of the OCs. In vivo and in vitro experiments show that both nanoparticles have noticeable targeting effects on OCs. This suggests that dual-targeting nanoparticles designed for different functional periods of OC can be well targeted to the corresponding OC, and further promote the more precise delivery of drugs used to treat OP.
Insights
New dual-targeting nanoparticles effectively target osteoclasts (OCs) at various functional stages for osteoporosis treatment. This breakthrough offers precise drug delivery, improving therapeutic outcomes for bone diseases.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Osteoporosis Research
Background:
- Osteoclast (OC) dysfunction is a key factor in osteoporosis (OP) pathogenesis.
- Current drug delivery systems lack specificity for targeting OCs at different developmental stages.
Purpose of the Study:
- To design and evaluate dual-targeting nanoparticles for precise OC drug delivery.
- To target both OC precursors and mature OCs at distinct functional phases.
Main Methods:
- Constructed dual-targeted nanoparticles utilizing calcitonin gene-related peptide receptor (CGRPR) and TRAP peptides.
- Grafted nanoparticles with hyaluronic acid (HA) for CD44 receptor binding on OCs.
- Performed in vivo and in vitro experiments to assess nanoparticle targeting efficacy.
Main Results:
- Both nanoparticle designs demonstrated significant targeting capabilities for OCs.
- The dual-targeting approach successfully targeted OCs during different functional periods.
- Enhanced targeting facilitates more precise delivery of osteoporosis therapeutics.
Conclusions:
- Dual-targeting nanoparticles offer a promising strategy for advanced OC-specific drug delivery.
- This approach can improve the efficacy and precision of osteoporosis treatments.
- Further development could lead to novel therapeutic solutions for bone-related disorders.
